LISATA THERAPEUTICS INC (LSTA)
US1280583022 - Common Stock
LSTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. While LSTA seems to be doing ok healthwise, there are quite some concerns on its profitability. LSTA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year LSTA has reported negative net income.
In the past year LSTA has reported a negative cash flow from operations.
LSTA had negative earnings in each of the past 5 years.
In the past 5 years LSTA always reported negative operating cash flow.
1.2 Ratios
LSTA has a Return On Assets of -54.29%. This is comparable to the rest of the industry: LSTA outperforms 44.88% of its industry peers.
LSTA has a Return On Equity (-61.56%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -54.29% | ||
| ROE | -61.56% | ||
| ROIC | N/A |
ROA(3y)-46.9%
ROA(5y)-46.91%
ROE(3y)-51.49%
ROE(5y)-54.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LSTA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LSTA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LSTA has been increased compared to 5 years ago.
LSTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
LSTA has an Altman-Z score of -16.61. This is a bad value and indicates that LSTA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.61, LSTA is not doing good in the industry: 84.92% of the companies in the same industry are doing better.
LSTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.61 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
LSTA has a Current Ratio of 8.03. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
LSTA has a better Current ratio (8.03) than 73.07% of its industry peers.
A Quick Ratio of 8.03 indicates that LSTA has no problem at all paying its short term obligations.
LSTA has a better Quick ratio (8.03) than 73.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.03 | ||
| Quick Ratio | 8.03 |
3. Growth
3.1 Past
LSTA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.34%.
EPS 1Y (TTM)6.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, LSTA will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.47% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.73%
EPS Next 2Y3.39%
EPS Next 3Y13.81%
EPS Next 5Y8.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LSTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LSTA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LSTA's earnings are expected to grow with 13.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.39%
EPS Next 3Y13.81%
5. Dividend
5.1 Amount
No dividends for LSTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LISATA THERAPEUTICS INC
NASDAQ:LSTA (1/3/2025, 8:00:01 PM)
3.85
+0.28 (+7.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners9.04%
Inst Owner Change1.98%
Ins Owners5.05%
Ins Owner Change7.18%
Market Cap32.30M
Analysts82.22
Price Target14.28 (270.91%)
Short Float %0.28%
Short Ratio1.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.09%
Min EPS beat(2)21.31%
Max EPS beat(2)22.88%
EPS beat(4)4
Avg EPS beat(4)20.9%
Min EPS beat(4)12.1%
Max EPS beat(4)27.3%
EPS beat(8)8
Avg EPS beat(8)22.26%
EPS beat(12)10
Avg EPS beat(12)-44.77%
EPS beat(16)12
Avg EPS beat(16)-38.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.6%
EPS NY rev (1m)6.03%
EPS NY rev (3m)8.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.96 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.51
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-2.25
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0
BVpS4.02
TBVpS3.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -54.29% | ||
| ROE | -61.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-46.9%
ROA(5y)-46.91%
ROE(3y)-51.49%
ROE(5y)-54.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.03 | ||
| Quick Ratio | 8.03 | ||
| Altman-Z | -16.61 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)171.43%
Cap/Depr(5y)109.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.23%
EPS Next Y-7.73%
EPS Next 2Y3.39%
EPS Next 3Y13.81%
EPS Next 5Y8.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.95%
EBIT Next 3Y-3.19%
EBIT Next 5Y-3.25%
FCF growth 1Y3.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.12%
OCF growth 3YN/A
OCF growth 5YN/A